# 1 Quality of life profile of methadone maintenance treatment patients in Ho Chi

- 2 Minh City, Vietnam
- 3

# 4 Authors:

- 5 Vu Thu Trang<sup>a,\*</sup>, Le Ngoc Tu<sup>b,\*</sup>, Vu Thi Tuong Vi<sup>c</sup>, Khuong Quynh Long<sup>a</sup>, Le Huynh Thi Cam
- 6 Hong<sup>c,d</sup>, Tieu Thi Thu Van<sup>e</sup>, Do Van Dung<sup>c,d</sup>
- 7 \*These authors contribute equally to this work and act as co-first authors
- 8
- 9 <sup>a</sup>Hanoi University of Public Health, Vietnam
- 10 <sup>b</sup>Department of Disease Control and Prevention, Pasteur Institute of Ho Chi Minh City, Vietnam
- 11 <sup>c</sup>Vietnam HIV Addiction Technology Transfer Center University of Medicine and Pharmacy at
- 12 Ho Chi Minh City, Vietnam
- 13 <sup>d</sup>University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam
- 14 <sup>e</sup>Prevention HIV/AIDS Center Ho Chi Minh City HIV/AIDS Association, Vietnam
- 15 16

# 17 **Corresponding author:**

- 18 Vu Thi Tuong Vi
- 19 Vietnam HIV Addiction Technology Transfer Center University of Medicine and Pharmacy at
- 20 Ho Chi Minh City, Vietnam, 217 Hong Bang Street, Ward 11, District 5, Ho Chi Minh City,
- 21 Vietnam.
- 22 Phone: +84 (0) 908 577 767; Email: tuongvipac@gmail.com
- 23
- 24

# 25 **Declarations**

- 26 Ethics approval and consent to participate
- 27 All procedures performed in studies involving human participants were in accordance with the
- 28 ethical standards of The Institution Review Board of Ho Chi Minh City HIV/AIDS Center (IRB-
- 29 02-2018, dated 10/08/2018). All participants provided signed informed consent.

#### **30 Consent for publication**

- 31 Not applicable.
- 32 Availability of data and material
- 33 Available upon request to the corresponding author
- 34 **Conflict of interest**
- 35 No potential conflict of interest was reported by the authors.
- 36 Funding
- 37 This study was supported by the South Vietnam HIV Addiction Technology Transfer Center and
- 38 Ho Chi Minh City HIV/AIDS Center

#### 39 Authors' contributions

- 40 VTT: Conducted data analysis and result explanation, drafted the manuscript
- 41 LNT: Collected the data, conducted data analysis and result explanation, drafted the manuscript
- 42 KQL: Designed the study, conducted data analysis and result explanation, provided editorial input
- 43 VTTV: Designed the study, provided editorial input
- 44 LHTCH: Participated in study design, provided editorial input
- 45 TTTV: Participated in study design, provided editorial input
- 46 DVD: Participated in study design, provided editorial input
- 47 All authors read and approved the final manuscript.
- 48

# 49 Acknowledgements

- 50 The authors would like to thank all MMT patients who participated in this study, colleagues in the
- 51 South Vietnam HIV Addiction Technology Transfer Center and Ho Chi Minh City HIV/AIDS
- 52 Center, District 4 and District 8 MMT clinics for supporting this research.
- 53

#### 54 Quality of life profile of methadone maintenance treatment patients in Ho Chi

55 Minh City, Vietnam

56

#### 57 Abstract

Aim: To determine the health-related quality of life (HRQoL) of methadone maintenance
treatment patients in Ho Chi Minh City, Vietnam.

60 Subject and Methods: A cross-sectional study was conducted in 967 patients treating at two 61 methadone clinics in Ho Chi Minh City, in 2018. Patient's health-related quality of life was 62 estimated using the EQ-5D-5L and Visual analogue scale (VAS). Tobit regressions were used to

63 identify factors related to patient's health-related quality of life.

**Results:** Overall, the mean EQ-5D-5L utility and EQ-VAS indexes were 0.96 (SD = 0.12) and

65 75.8 (SD=15.5), respectively. Factors related with a higher EQ-5D-5L score included peoples who

are single, and have a higher monthly income (more than 4 million VND per month), while patients

aged under 30 years old, have full-time employment, and have higher education were associated

with a higher EQ-VAS score. HIV was associated with lower scores of both EQ-5D-5L and EQ-

69 VAS ( $\beta = -0.07$  (95%CI: -0.13; -0.01), and  $\beta = -7.10$  (95%CI: -9.23; -4.98), respectively).

Conclusion: HRQoL measurement provides valuable information for the policymaker to adopt suitable decisions on opioid dependence treatment. The finding shows that patients with education, job situation, and socioeconomic status are the related elements with higher HRQoL, which suggested that the policymakers and physicians should pay more attention to these aspects while working on treatment plan for drug users.

75 Key words: HRQoL, methadone maintenance treatment, quality of life, Vietnam

# 76 Introduction

Since the first introduction in 1947, Methadone maintenance treatment (MMT) has been proved 77 78 as an efficacious drug treatment modality for heroin addiction (Herget 2005; O'Donnell and Vogenberg 2011; World Health 2004). In Vietnam, the MMT program was originated in 2008, 79 with approximately 53,000 drug users have received treatment in 336 nationwide MMT clinics up 80 to 31th December 2019 (Nguyen et al. 2017c). Coverage of the MMT program in Vietnam had 81 82 reached 28% of the total number of people addicted to opiates, treatment adherence rate after six 83 months was 83%, corresponding to the graded good (by World Health Organization standard is 80%). Methadone treatment in Vietnam has been shown to be effective in helping patients reduce 84 and eventually stop using illegal drugs, improve health (reduce HIV infection and diseases 85 86 transmitted through blood, physical enhancement, physical and mental rehabilitation) (MOH 2020). 87

Health-related quality of life (HRQoL) is a multidimensional construct related to the physical, 88 mental, emotional, and social functioning of an individual, based on their perceptions. HRQoL is 89 becoming increasingly important in assessing treatment outcomes since most opioid-dependent 90 people often experience negative socioeconomic consequences and social exclusion, let alone 91 suffer from adverse health outcomes and high rates of overdose deaths (Strada et al. 2017). Several 92 93 studies have found the opioid users or those receiving MMT tend to have impaired HRQoL caused 94 by their comorbid infectious diseases, such as hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV (Astals et al. 2008; Korthuis et al. 2008). For instance, Astals et al. conducted a study to 95 assess the quality of life between the general European population and opioid users, the result 96 97 found that the former group had significantly lower scores compared to the general population (Astals et al. 2008). Other studies used the patient's HRQoL as outcome indicator to evaluate the 98

99 effectiveness of MMT program (Karow et al. 2011; Lashkaripour et al. 2012; Strada et al. 2017).
100 For example, research conducted in HCMC and Hai Phong showed the number of patients with
101 good HRQoL increased from 16% to 55% after 3 months of treatment (Vietnamese Ministry of
102 Health 2014).

Although many studies have explored the HROoL of opioid users, only a few have examined 103 104 variations in their scores and determinants factors (Korthuis et al. 2008; Nguyen et al. 2017b; Quyen et al. 2020). A comprehensive understanding of the relationships between HRQoL and 105 MMT is important for developing response strategies to the opioid. This is especially of 106 107 importance in the context of Vietnam, there are little shreds of evidence that summarize specific linking associated factors to the quality of life for people with opioid dependence. This study was 108 conducted to examine the HRQoL and its determinants among MMT patients in Ho Chi Minh 109 City, Vietnam. 110

#### 111 Method

#### 112 Setting and participants

113 This cross-sectional study was conducted at two MMT clinics in District 8 and District 4, Ho Chi 114 Minh City (HCMC). The inclusion criteria for the survey included:  $(1) \ge 18$  year olds, (2) currently 115 visiting the clinic during the study period and (3) having the ability to answer the questionnaire. 116 There were 1,039 eligible patients in two clinics, among them, 967 people (93.1%) agreed and 117 participated in the study.

#### 118 **Procedure and measurement**

Patients who met the inclusion criteria were invited to private rooms. Subsequently, they were given the verbal introduction of the study and confirmed their enrollment by signing the consent form. Those who refused to participate continued their usual treatment at the clinic. The

questionnaire was conducted by face-to-face interviews in around 25-30 minutes. Data collectors
were well-trained preventive medicine doctors from Addiction Technology Transfer Center,
University of Medicine and Pharmacy at Ho Chi Minh City. Clinic staffs were not involved in this
process to avoid potential bias.

#### 126 *Outcome variables*

127 The primary outcome of this study was quality of life measured by The EuroQol-five (EQ-5D-5L) and The Visual Analogue Scale (EQ-VAS). The EQ-5D-5L includes five dimensions which 128 describe different aspects of life: mobility, self-care, usual activities, pain/discomfort, and 129 anxiety/depression. In each dimension, a Likert rating scale of five response levels (no problems-130 code 1, slight problems-code 2, moderate problems-code 3, severe problems- code 4, unable 131 to/extreme problems-code 5) is used. The numbers for each dimension can be combined to a 5-132 digit code ranging from 11111 (no problems) to 55555 (worst health). The overall EQ-5D-5L score 133 is calculated by using the crosswalk value set in the data of EuroQuoL (EuroQol Research 134 135 Foundation 2019).

The Visual Analogue Scale (EQ-VAS) is developed to assess the self-rated health of patients. The
scale ranges from 0 (*the worst health you can imagine*) to 100 points (*the best health you can imagine*) (EuroQol Research Foundation 2019). The Vietnamese version of EQ-5D-5L and EQVAS have been translated, validated and used in many previous studies in Vietnam (Nguyen et al. 2017a; Tran et al. 2018; Tran et al. 2012).

#### 141 The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)

The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) was included to
investigate the risk of concurrent drug use among respondents. The ASSIST was developed by the
Word Health Organization (WHO) and designed to be culturally neutral and useable in primary

145 care setting across a variety of cultures. The tool contains a total of 8 questions collecting 146 information about lifetime use of 9 common substances, use of these substances and associated 147 problems over the last 3 months. Patients being assessed as *"medium risk"* or *"high risk"* were 148 defined as hazardous substance users (World Health Organization (WHO) 2010).

- 149 *Clinical data extraction*
- 150 MMT treatment information of participants including duration on MMT, daily methadone dosage,
- number of doses missed within last 3 months and comorbidities (HIV, tuberculosis, hepatitis B,

and hepatitis C) were extracted from the medical records.

153 Urine samples of respondents were collected and tested for methamphetamine (a substance of ATS

154 group) using rapid urine test (ABON, Biopham Co. Ltd). This process was implemented by well-

trained laboratory staffs.

#### 156 Data analysis

Descriptive statistics were used to summarize the data, with frequencies and percentages for categorical variables and means with standard deviations (SD) or median with inter-quartile ranges (IQR) for quantitative variables. To detect the differences between EQ-5D-5L and EQ-VAS scores among respondents, we used t-tests, ANOVA tests or Wilcoxon Rank Sum tests when appropriate. Tobit regressions were conducted to identify factors associated with EQ-5D-5L and EQ-VAS scores. A significant level of p < 0.05 was used for all statistical tests. All analyses were carried out using Stata v16 (Stata Corp, College Station, TX).

164 *Ethics* 

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institution Review Board of Ho Chi Minh City HIV/AIDS Center (IRB-

167 02-2018, dated 10/08/2018). All participants provided signed informed consent.

#### 168 **Results**

A total of 967 participants enrolled into the study. Patients' demographic characteristics are shown 169 170 in Table 1. Most of participants were male (89.9%), aged from 30 to 49 (81.8%), having full-time job (74.3%) and being married or living with partners (46.4%). Nearly a haft of respondents 171 (47.8%) finished secondary school and had a monthly income from 4 to 8 million VND (44.8%). 172 The majority of patients had ever injected drugs (78.0%), while only 12.4% respondents still 173 injected drugs within the past three months. About 60% of them had the duration on MMT 174 175 between 1 to 5 years, with prevalent dose for methadone was 60-120 mg/day (41.2%). Moreover, 44.8% participants reported missing at least one dose in past 3 months. The proportions of 176 participants with positive HIV, HBV, HCV and tuberculosis were 33.9%, 9.7%, 41.9% and 1.0%, 177 178 respectively.

179

#### (Table 1 is about here)

Table 2 shows profiles of EQ-5D-5L domains according to frequencies of each item response. The
highest proportion of respondents reporting any problems was in pain/discomfort domain (14.2%),
followed by anxiety/ depression (14.1%), usual activities (7.2%) and mobility (6.7%), the lowest
percentage was in Self-care (2.8%).

184

#### (Table 2 is about here)

The mean EQ-5D-5L utility scores and EQ-VAS scores by different characteristics are summerized in table 3. Overall, the mean EQ-5D-5L and EQ-VAS indexes were 0.96 (SD=0.12) and 75.8 (SD=15.5), respectively. Lower EQ-5D-5L and EQ-VAS scores were found older patients and those having lower education, and having unstable job. Patients who had monthly income under 4 million VND had lower EQ-5D-5L and EQ-VAS indexs compared to other groups (p<0.001). We also found significant differences on EQ-5D-5L and EQ-VAS scores in term of

191	duration on MMT, daily methadone dose, dose missed in the last 3 months. Notably, people being
192	positive with HIV, hepatitis B, C or having ARV treatment also had lower EQ-5D-5L score or EQ-
193	VAS index than their counterparts.
194	(Table 3 is about here)
195	Table 4 shows the association between EQ-5D-5L and EQ-VAS scores and different kinds of
196	substance use. Patients being hazardous ATS and cannabis users had 5 points and 7 points lower
197	than the others in EQ-VAS index, respectively ( $p$ <0.001 for ATS use and $p$ =0.043 for cannabis
198	use).
199	(Table 4 is about here)
200	Table 5 illustrates ten most common EQ-5D-5L health states, which accounted for 91.3% of
201	participants. Health conditions "11111" (full health), "11112" (slightly problems in
202	anxiety/depression) and "11121" (slightly problems in pain/discomfort) were the most frequent

203 statuses among respondents.

204

#### (Table 5 is about here)

The final multivariate model revealed four factors related to EQ-5D-5L scores. Patients who were 205 married/live with partners and those who were divorced/separated/widowed had lower EQ-5D-5L 206 207 scores, compared with patients who were single, ( $\beta$ =-0.08; 95%CI: -0.14,-0.01 and  $\beta$ =-0.09; 95%CI: -0.17,-0.01, respectively). Similarly, the lower scores were found in patients who had 208 unstable job compared to those having full-time job ( $\beta$ =-0.10; 95%CI: -0.19, -0.01 in part-time job 209 and  $\beta$ =-0.09; 95%CI:-0.18,-0.01 in unemployed) or being positive with HIV ( $\beta$ =-0.07; 95%CI: -210 0.13,-0.01). By contrast, patients had higher EQ-5D-5L score when they got higher monthly 211 income ( $\beta$ =0.12; 95%CI: 0.04,0.20 in 4-8 million VND and  $\beta$ =0.12; 95%CI: 0.02,0.21 in >8 212 213 million VND).

Similar results were found in the final model for EQ-VAS scores. The lower EQ-VAS scores were found in patients having unstable job as compared to those having full-time job ( $\beta$ =-4.24; 95%CI: -7.38,-1.08 for part-time job and  $\beta$ =-5.17; 95%CI: -7.98,-2.36 for unemployed), having HIV positive serostatus ( $\beta$ =-7.10; 95%CI: -9.23,-4.98), aged  $\geq$  50 years ( $\beta$ =-12.78; 95%CI: -17.56,-8.01) and having hazardous ATS use ( $\beta$ =-5.97; 95%CI: -8.60,-3.35). Whereas, patients who finished secondary school or above had higher EQ-VAS scores than those who did not. (Table 6) (Table 6 is about here)

#### 221 **Discussion**

The mean score of EQ-5D-5L and EQ-VAS in our study were 0.96 (SD = 0.12) and 75.8 (SD=15.5), respectively, which were higher than that of the methadone patients in the North mountain area in Vietnam 0.88 (SD = 0.20) and long-term treatment with methadone patients in Norway 0.699 (0.25) (Nguyen et al. 2017b). This difference could happen due to the differences in geographical location, social distinctions, economic status, and culture.

227 Our results indicated that MMT patients aged from 30 to 50 years old usually did not experience 228 significant pain/discomfort and anxiety/depression symptoms in their daily life. These symptoms 229 were more frequently reported among patients who were lower than 30 or older than 50 years old. 230 This finding was consistent with the previous study in Vietnam, in which, the prevalence of anxiety/depression was the most common symptom among study participants (Tran et al. 2011). 231 The two problems (pain/discomfort and anxiety/depression) were also the most frequently reported 232 by MMT patients in Poland (Golicki and Niewada 2017). Notably, 77.8% of participants in our 233 study reported with the health states as 11111 (perfect health state) indicated that the quality of life 234 235 among MMT patients in Vietnam was relatively high.

We found that the patient's age, education, marital status, employment status, and socioeconomic 236 status were significantly associated with their HRQoL. Specifically, the HRQoL scores were lower 237 238 among older patients, which is in line with previous research in Vietnam, Uruguay, England and Germany (Augustovski et al. 2016; Feng et al. 2015; Hinz et al. 2014). Patients with higher 239 education, being employed, and having high socioeconomic had higher HROoL than the other 240 241 groups. It could be explained that people with stable income and jobs are easier to access MMT services, and people with higher education are more likely to adopt/adherence the MMT treatment 242 and have the self-awareness to break the addiction (Quyen et al. 2020; Sadeghi et al. 2017). 243

Consistent with previous studies, our study revealed patients involving in the MMT program more
than five years had lower score of EQ-VAS as compared to those being treated in less than 5 years.
(Babaie and Razeghi 2013; Quyen et al. 2020). The results also showed patients who missed dose
had a higher score than adherence patients. Since the causal relationship has not been confirmed
yet, this finding raises the question that MMT treatment effective may lead to miss dose decision
in MMT patient.

In the present study, 33.9% of participants had HIV, and 96.8% of them were on ARV treatment, among these, we found patients living with HIV had lower HRQoL. According to previous studies, comorbidities contribute to lower HRQoL because they lead to poorer health status (Tran 2012; Tran et al. 2011; Wang et al. 2014). ARVs have the effect of inhibiting the reproduction of HIV but can bring side effects for the users. Therefore, it is as expected that the lower HRQoL scores were found among these patients. However, the most difficult thing that these patients had to face was experiencing social stigma and discrimination (Quyen et al. 2020).

Besides, HIV patients also bear the burden of treatment-related costs and are limited in dailyactivities (Wang et al. 2014). In Vietnam, health insurance does not cover the costs of daily

consumables that methadone used but pays for routine laboratory tests and costs for treatment of adverse effects and comorbidities in compliance with regulations by Vietnam's Ministry of Health. Accordingly, drug users with insurance when participating in MMT are less worried about paying additional treatment and laboratory test costs. The previous study has shown this policy helps insurance patients sought and received treatment more promptly, sufficiently, and properly than those who had to pay for treatment by themselves (Quyen et al. 2020).

In our study, patients being hazardous ATS users had lower EQ-VAS scores than their 265 counterparts. A previous study demonstrated that drug use among MMT patients was still a rising 266 267 problem that could decrease their health and quality of life (Le et al. 2021). Long-term ATS use negatively leads to intoxication, emotional disorder, anxiety and increases high-risk sexual 268 behaviors such as unprotected sex and sex with multiple partners (Radfar and Rawson 2014; 269 Volkow et al. 2007). Our finding indicates the need for programs on controlling ATS use among 270 MMT patients, including screening, provide urine testing for the patient as a regular test. Besides, 271 272 other interventions to help patients withdraw from ATS are needed to maintain better outcomes 273 for MMT patients (Shariatirad et al. 2013).

Our study has several limitations. First, as a cross-sectional survey, the results could not be interpreted as causal relationship. Second, as all the participants are recruited in Ho Chi Minh City, the results might not be generalized for MMT patients in other areas. Further studies in Vietnam are needed to thoroughly explore the associated factors with HRQoL among MMT patients, including the different elements between male and female patients, social stigma, or psychology events that could affect HRQoL.

# 281 Conclusion

HRQoL measurement provides valuable information for the policymaker to adopt suitable decisions on opioid dependence treatment. The finding shows that patients with education, job situation, and socioeconomic status are the related elements with higher HRQoL, which suggested that the policymakers and physicians should pay more attention to these aspects while working on treatment plan for drug users.

#### 287 **Conflict of interest**

288 The authors declare that they have no conflict of interest.

# 290 **References**

- Astals M, Domingo-Salvany A, Buenaventura CC, Tato J, Vazquez JM, Martín-Santos R, Torrens
   M (2008) Impact of substance dependence and dual diagnosis on the quality of life of
   heroin users seeking treatment Subst Use Misuse 43:612-632
   doi:10.1080/10826080701204813
- Augustovski F et al. (2016) An EQ-5D-5L value set based on Uruguayan population preferences
  Qual Life Res 25:323-333 doi:10.1007/s11136-015-1086-4
- Babaie E, Razeghi N (2013) Comparing the effects of methadone maintenance treatment,
  therapeutic community, and residential rehabilitation on quality of life and mental health
  of drug addicts Addict Health 5:16-20
- 300 EuroQol Research Foundation (2019) EQ-5D-5L User Guide. Rotterdam, Netherlands
- Feng Y, Devlin N, Herdman M (2015) Assessing the health of the general population in England:
  how do the three- and five-level versions of EQ-5D compare? Health Qual Life Outcomes
- 303 13:171 doi:10.1186/s12955-015-0356-8
- Golicki D, Niewada M (2017) EQ-5D-5L Polish population norms Arch Med Sci 13:191-200
  doi:10.5114/aoms.2015.52126
- Herget G (2005) Methadone and buprenorphine added to the WHO list of essential medicines.Canada
- Hinz A, Kohlmann T, Stöbel-Richter Y, Zenger M, Brähler E (2014) The quality of life
  questionnaire EQ-5D-5L: psychometric properties and normative values for the general
  German population Qual Life Res 23:443-447 doi:10.1007/s11136-013-0498-2
- Karow A, Verthein U, Pukrop R, Reimer J, Haasen C, Krausz M, Schäfer I (2011) Quality of life
  profiles and changes in the course of maintenance treatment among 1,015 patients with

- 313
   severe
   opioid
   dependence
   Subst
   Use
   Misuse
   46:705-715

   314
   doi:10.3109/10826084.2010.509854
- Korthuis T et al. (2008) Health-Related Quality of Life in HIV-Infected Patients: The Role of
  Substance Use AIDS patient care and STDs 22:859-867 doi:10.1089/apc.2008.0005
- 317 Lashkaripour K, Bakhshani NM, Sadjadi SA (2012) Quality of life in patients on methadone
- 318 maintenance treatment: a three-month assessment J Pak Med Assoc 62:1003-1007
- Le NT et al. (2021) Prevalence of Amphetamine-Type Stimulant Use and Related Factors among
- 320 Methadone Maintenance Patients in Ho Chi Minh City Vietnam: A Cross-Sectional Study
- Journal of psychoactive drugs:1-9 doi:10.1080/02791072.2020.1871126
- MOH (2020) Draft Guide to pilot implementation of multi-day methadone supply for patients
   receiving opioid addiction treatment. Vietnamese Ministry of Health,
- Nguyen LH et al. (2017a) Quality of life and healthcare service utilization among methadone
   maintenance patients in a mountainous area of Northern Vietnam Health and quality of life
   outcomes 15:77
- Nguyen LH et al. (2017b) Quality of life and healthcare service utilization among methadone
   maintenance patients in a mountainous area of Northern Vietnam Health Qual Life
   Outcomes 15:77 doi:10.1186/s12955-017-0633-9
- Nguyen LH et al. (2017c) Psychological Distress Among Methadone Maintenance Patients in
   Vietnamese Mountainous Areas AIDS Behav 21:3228-3237 doi:10.1007/s10461-017 1779-5
- O'Donnell J, Vogenberg FR (2011) Applying legal risk management to the clinical use of
   methadone P T 36:813-822

335	Quyen BTT, Nguyen LT, Phuong VTV, Hoang LT (2020) Quality of life in methadone
336	maintenance treated patients in Long An, a southern province of Vietnam Health Psychol
337	Open 7:2055102920953053-2055102920953053 doi:10.1177/2055102920953053
338	Radfar SR, Rawson RA (2014) Current research on methamphetamine: epidemiology, medical
339	and psychiatric effects, treatment, and harm reduction efforts Addict Health 6:146-154
340	Sadeghi N, Davaridolatabadi E, Rahmani A, Ghodousi A, Ziaeirad M (2017) Quality of life of
341	adolescents and young people arrive at an addiction treatment centers upon their admission,
342	and 1, 4 and 8 months after methadone maintenance therapy J Educ Health Promot 6:95-
343	95 doi:10.4103/jehp.jehp_297_13
344	Shariatirad S, Maarefvand M, Ekhtiari H (2013) Methamphetamine use and methadone
345	maintenance treatment: an emerging problem in the drug addiction treatment network in
346	Iran Int J Drug Policy 24:e115-116 doi:10.1016/j.drugpo.2013.05.003
347	Strada L, Vanderplasschen W, Buchholz A, Schulte B, Muller AE, Verthein U, Reimer J (2017)
348	Measuring quality of life in opioid-dependent people: a systematic review of assessment
349	instruments Qual Life Res 26:3187-3200 doi:10.1007/s11136-017-1674-6
350	Tran BX (2012) Quality of life outcomes of antiretroviral treatment for HIV/AIDS patients in
351	Vietnam PloS one 7:e41062-e41062 doi:10.1371/journal.pone.0041062
352	Tran BX, Nguyen LH, Nguyen CT, Latkin CA (2018) Health-related work productivity loss is low
353	for patients in a methadone maintenance program in Vietnam The International journal on
354	drug policy 60:1-7 doi:10.1016/j.drugpo.2018.07.007
355	Tran BX, Ohinmaa A, Nguyen LT (2012) Quality of life profile and psychometric properties of
356	the EQ-5D-5L in HIV/AIDS patients Health and Quality of Life Outcomes 10:132
357	doi:10.1186/1477-7525-10-132

358	Tran BX, Ohinmaa A, Nguyen LT, Nguyen TA, Nguyen TH (2011) Determinants of health-related
359	quality of life in adults living with HIV in Vietnam AIDS care 23:1236-1245
360	doi:10.1080/09540121.2011.555749

361 Vietnamese Ministry of Health FU (2014) Evaluate the effectiveness of methadone treatment for

opioid addiction treatment in Hai Phong and Ho Chi Minh City for the period 2009-2011.

- 363 Volkow ND, Wang GJ, Fowler JS, Telang F, Jayne M, Wong C (2007) Stimulant-induced
- enhanced sexual desire as a potential contributing factor in HIV transmission The
  American journal of psychiatry 164:157-160 doi:10.1176/ajp.2007.164.1.157
- 366 Wang Y et al. (2014) Reduced responses to heroin-cue-induced craving in the dorsal striatum:

# 367 effects of long-term methadone maintenance treatment Neurosci Lett 581:120-124 368 doi:10.1016/j.neulet.2014.08.026

- World Health O (2004) Proposal for the inclusion of methadone in the WHO model list of essential
  medicines.
- World Health Organization (WHO) (2010) The Alcohol, Smoking and Substance Involvement
   Screening Test (ASSIST). Switzerland

Characteristics	Total	
	n	%
Gender Male	967 869	89.9
Female	98	10.1
Age	961	1011
< 30	111	11.6
30 - 49	786	81.8
> 50	64	6.6
Education	966	
Primary school or less	210	21.7
Secondary school	462	47.8
High school or above	294	30.4
Occupation	967	
Full-time job	718	74.3
Part-time job	108	11.2
Unemployed	141	14.5
Marital status	966	
Single	363	37.6
Married/live with partners	448	46.4
Divorced/Separated/ Widowed	155	16.0
Monthly income	965	
< 4 million VND	330	34.2
4 - 8 million VND	432	44.8
> 8 million VND	203	21.0
Ever injected drugs	967	
Yes	754	78.0
No	213	22.0
Injecting drug use within the past 3 months	965	
Yes	120	12.4
No	845	87.6
Duration on MMT	965	
< 1 year	128	13.3
1-5 years	580	60.1
> 5 years	257	26.6
Daily Methadone dose (mg)	967	
< 60 mg/day	245	25.3
60 - 120 mg/day	398	41.2
>120 mg/day	324	33.5

# **Table 1: Demographic characteristics of respondents**

Characteristics	Total		
	n	%	
Dose missed in the last 3 months	967		
Yes	433	44.8	
No	534	55.2	
HIV positive	967		
Yes	328	33.9	
No	639	66.1	
ARV treatment	312		
Yes	302	96.8	
No	10	3.2	
Tuberculosis	967		
Yes	10	1.0	
No	957	99.0	
Hepatitis B	967		
Yes	94	9.7	
No	873	90.3	
Hepatitis C	967		
Yes	405	41.9	
No	562	58.1	

375

Notes: n, number of participants; MMT, methadone maintenance treatment; ARV, antiretroviraltreatment.

# Table 2: Profiles of EQ-5D-5L by age group

Domains	< 30		30-49		≥ <b>50</b>		Total	Total	
	n	%	n	%	n	%	n	%	
Mobility No problems Slight problems	111 102 6	91.9 5.4	786 741 29	94.2 3.7	64 54 3	84.4 4.7	967 902 38	93.3 3.9	
Moderate problems	2	1.8	8	1.0	3	4.7	14	1.5	
Severe problems	1	0.9	7	1.0	4	6.3	12	1.2	
Unable to walk	0	0.0	1	0.1	0	0.0	1	0.1	
Self-care	111		786		64		967		
No problems	108	97.3	767	97.5	60	93.8	940	97.2	
Slight problems	1	0.9	9	1.2	1	1.6	11	1.2	
Moderate problems	2	1.8	6	0.8	2	3.0	9	0.9	
Severe problems	0	0.0	3	0.4	1	1.6	6	0.6	
Extreme problems	0	0.0	1	0.1	0	0.0	1	0.1	
Usual activities	111		786		64		967		
No problems	100	90.1	734	93.3	58	90.6	897	92.8	
Slight problems	7	6.3	32	4.1	1	1.6	40	4.1	
Moderate problems	2	1.8	15	1.9	3	4.7	21	2.2	
Severe problems	2	1.8	3	0.4	2	3.1	7	0.7	
Unable to do	0	0.0	2	0.3	0	0.0	2	0.2	
Pain/Discomfort	111		786		64		967		
No pain	97	87.4	682	86.7	45	70.3	829	85.8	
Slight pain	10	9.0	70	8.9	8	12.5	88	9.1	
Moderate pain	2	1.8	28	3.6	8	12.5	39	4.0	
Severe pain	2	1.8	4	0.5	2	3.1	8	0.8	
Extreme pain	0	0	2	0.3	1	1.6	3	0.3	
Anxiety/Depression	111		786		64		967		
Not anxious/depressed	94	84.7	682	86.7	50	78.1	831	85.9	
Slightly	14	12.6	72	9.2	8	12.5	94	9.8	
Moderately	2	1.8	24	3.1	3	4.7	30	3.1	
Severely	1	0.9	5	0.6	2	3.1	8	0.8	
Extremely	0	0	3	0.4	1	1.6	4	0.4	

379

	EQ-5D-5	L scores		EQ-VAS		
	Mean	SD	p-value	Mean	SD	p-value
Total	0.96	0.12		75.8	15.5	
Gender						
Male	0.96	0.11	0.249	75.8	15.2	0.949
Female	0.94	0.19		75.7	17.7	
Age						
< 30	0.96	0.11	< 0.001	79.9	15.5	< 0.001
30 - 49	0.96	0.11		75.9	15.1	
$\geq$ 50	0.9	0.2		67.3	16.6	
Education						
Primary school or less	0.93	0.18	< 0.001	72.2	17.1	< 0.001
Secondary school	0.96	0.11		76.2	15.7	
High school or above	0.97	0.07		77.6	13.4	
Occupation						
Full-time job	0.97	0.1	< 0.001	77.5	14.4	< 0.001
Part-time job	0.94	0.12		71.4	15.5	
Unemployed	0.91	0.19		70.5	18.6	
Marital status						
Single	0.97	0.09	0.058	76.2	15.1	0.791
Married/live with partners	0.95	0.13		75.6	15.3	
Divorced/Separated/	0.04	0.15		75.0	160	
Widowed	0.94	0.15		/5.3	16.9	
Monthly income	0.00	0.45	0.001	<b>5</b> 0.0	1.5	0.001
< 4 million VND	0.93	0.17	<0.001	72.2	17.6	<0.001
4 - 8 million VND	0.97	0.08		77.1	14.1	
> 8 million VND	0.97	0.08		79	13.5	
Ever injected drugs						
Yes	0.96	0.12	0.62	75	15.6	0.005
No Injecting drug use within the past 3 months	0.96	0.12		78.4	14.9	
Yes	0.95	0.09	0.818	73.3	16.7	0.059
No	0.96	0.12		76.1	15.3	
Duration on MMT						
< 1 year	0.97	0.09	0.645	77.6	14.7	0.01
1-5 years	0.95	0.13		76.5	15.5	
> 5 years	0.96	0.11		73.4	15.7	

# 381 Table 3: EQ-5D-5L utility scores and EQ-VAS scores by different characteristics

Daily Methadone dose (mg)

	EQ-5D-5	EQ-5D-5L scores		EQ-VAS	EQ-VAS scores		
	Mean	SD	p-value	Mean	SD	p-value	
< 60 mg/day	0.96	0.10	0.138	77.8	14.8	< 0.001	
60 - 120 mg/day	0.96	0.10		76.7	15.5		
>120 mg/day	0.95	0.15		73.2	15.6		
Dose missed in the last 3 mont	hs						
Yes	0.97	0.1	0.047	76.4	14.5	0.271	
No	0.95	0.13		75.3	16.2		
HIV positive							
Yes	0.94	0.15	0.017	71.1	15.8	< 0.001	
No	0.96	0.1		78.2	14.8		
ARV treatment (n=312)	0.94	0.15					
Yes	0.94	0.15	< 0.001	70.3	15.7	0.012	
No	0.99	0.03		83	10.3		
Tuberculosis							
Yes	0.9	0.31	0.589	74.5	13	0.791	
No	0.95	0.12		75.8	15.5		
Hepatitis B							
Yes	0.94	0.16	0.315	72	15.2	0.013	
No	0.96	0.11		76.2	15.5		
Hepatitis C							
Yes	0.96	0.12	0.529	74.3	15.6	0.013	
No	0.95	0.12		76.8	15.3		

382

	EQ-5D-5L scores		EQ-VAS			
	Mean	SD	p-value	Mean	SD	p-value
Hazardous tobacco use (ASSIST $\geq$ 4)						
Yes (n=941)	0.96	0.11	0.418	75.8	15.5	0.954
No (n=26)	0.91	0.31		76.0	14.3	
Hazardous alcohol use (ASSIST $\geq 11$ )						
Yes (n=81)	0.95	0.09	0.707	76.0	15.2	0.888
No (n=886)	0.96	0.12		75.8	15.5	
Hazardous ATS use (ASSIST $\geq$ 4)						
Yes (n=161)	0.95	0.13	0.251	71.7	17.0	<0.001
No (n=806)	0.96	0.12		76.6	15.1	
Positive urine test with ATS						
Yes (n=246)	0.96	0.11	0.491	76.4	14.7	0.490
No (n=721)	0.96	0.12		75.6	15.8	
Hazardous opioids use (ASSIST $\geq$ 4)						
Yes (n=825)	0.96	0.12	0.171	75.7	15.5	0.564
No (n=142)	0.94	0.14		76.5	15.5	
Hazardous cannabis use (ASSIST $\geq$ 4)						
Yes (n=25)	0.91	0.16	0.112	69.6	13.7	0.043
No (n=942)	0.96	0.12		76.0	15.5	

# 384 Table 4: EQ-5D-5L utility scores and EQ-VAS scores by different substance uses

385

386 Notes: ASSIST, The Alcohol, Smoking and Substance Involvement Screening Test

Health states	Number	Percent	Cum%	Mean Utility	Mean VAS
11111	752	77.8	77.8	1.00	78.5
11112	37	3.8	81.6	0.94	74.6
11121	28	2.9	84.5	0.92	65.5
11122	20	2.1	86.6	0.85	72.4
11131	16	1.7	88.3	0.85	55.6
11211	7	0.7	89.0	0.95	71.4
11113	7	0.7	89.7	0.89	76.4
21111	6	0.6	90.3	0.93	80.0
11222	5	0.5	90.8	0.81	70.0
11221	5	0.5	91.3	0.87	67.0

# Table 5: Most frequent EQ-5D-5 L health states with mean utility scores and EQVAS scores

389

	EQ-5D-5L scores E0		EQ-VA	EQ-VAS scores			
	β	95%CI	p-value	β	95%CI	p-value	
Age	-	-	-				
< 30				1			
30 - 49				-2.45	[-5.59; 0.69]	0.126	
$\geq$ 50				-12.78	[-17.56; -8.01]	< 0.001	
Education	-	-	-				
Primary school or less				1			
Secondary school				2.92	[0.41; 5.43]	0.023	
High school or above				3.71	[0.98; 6.45]	0.008	
Marital status							
Single	1						
Married/live with partners	-0.08	[-0.14; -0.01]	0.021				
Divorced/Separated/ Widowed	-0.09	[-0.17; -0.01]	0.045				
Occupation							
Full-time job	1			1			
Part-time job	-0.10	[-0.19; -0.01]	0.031	-4.24	[-7.38; -1.08]	0.008	
Unemployed	-0.09	[-0.18; -0.01]	0.066	-5.17	[-7.98; -2.36]	< 0.001	
Monthly income				-	-	-	
< 4 million VND	1						
4 - 8 million VND	0.12	[0.04; 0.20]	0.003				
> 8 million VND	0.12	[0.02; 0.21]	0.013				
HIV positive							
No	1			1			
Yes	-0.07	[-0.13; -0.01]	0.036	-7.10	[-9.23; -4.98]	< 0.001	
Hazardous ATS use	-	-	-				
No				1			
Yes				-5.97	[-8.60; -3.35]	< 0.001	

# Table 6: Multivariate linear regression model of factors related to EQ-5D-5L and EQ-VAS scores

394 Notes: CI, confidence interval

395

396

397